Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹69.45
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.31B
Enterprise Value₹441.60M
Total Cash (Recent Filing)₹388.49M
Total Debt (Recent Filing)₹565.23M
Price to Earnings (P/E)112.0
Beta1.06
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.60
Price to Sales (P/S)1.28
P/FCF Ratio-6.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryReported strong revenue growth from 2024 to 2025 indicates expanding product uptake and market penetration in the formulations distribution business. Durable top-line expansion supports scale economies, higher absolute margins and reinvestment capacity over the next 2-6 months.
Margin SustainabilityConsistently solid gross and EBIT margins point to effective pricing and cost controls in the core marketing and distribution model. Margin strength is a structural advantage that supports free cash generation potential and resilience to modest revenue volatility.
Healthy Capital StructureA strong equity base and historically low debt-to-equity provide financial flexibility to fund working capital, absorb shocks, and finance strategic investments without immediate dependence on costly external funding, bolstering medium-term stability.
Bears Say
Negative Free Cash FlowNegative free cash flow driven by higher capex and operating cash outflows reduces internal funding for operations and growth. Over a multi-month horizon this raises reliance on external financing, which can constrain strategic flexibility and increase financing cost risk.
Volatile Net IncomeMaterial fluctuations in net income undermine earnings predictability and complicate budgeting and dividend policy. Persistent volatility can mask true operating performance and elevate investor and creditor scrutiny of recurring profitability.
Rising Total Debt TrendA notable uptick in total debt in 2025 signals a shift toward higher leverage. If sustained, rising debt increases interest obligations and reduces balance sheet flexibility, making the business more sensitive to cash-flow shortfalls over the coming months.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹69.45 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.31B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 52 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Currently, no data Available
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Gkb Ophthalmics Limited
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―